Entrada to receive $224 million upfront payment and $26 million equity investment
The oligonucleotide field is ever evolving at a rapid pace, as experts continue to optimize manufacturing processes, develop robust analytical methods, and ensure the quality and safety of oligonucleotide-based therapeutics.
Here are just some of the latest advancements that have been seen in this field…
- AAHI awarded a $9.9 million project to develop prototype intranasal bivalent influenza RNA vaccine candidate
- Vertex and Entrada Therapeutics Establish Collaboration to Discover and Develop Endosomal Escape Vehicle Therapeutics for Myotonic Dystrophy Type 1
- University of Texas and HDT Bio have received funding worth up to $87.4m in a project agreement from the US Government for developing saRNA vaccine technology
With this news in mind, leaders are gathering to join forces at the Oligonucleotide CMC & Analytical Development Summit, taking place this August.
To keep your finger on the pulse and stay up to speed with the latest discussions and movements wihtin this space, then join your peers at this cutting edge summit as we unlock the potential of oligonucleotides beyond rare disease to treat large patient populations for undruggable targets.
This summit will feature case studies and interactive discussions on the latest advancements and challenges in the field of oligonucleotide CMC and analytical development, with excellent opportunities to learn from and network with some of the brightest minds in the industry.
If you wish to stay up to date with the latest news and insights, have any questions or would like to learn more about these developments, get in touch today.
For the full scope of this year’s meeting, including the expert speaker faculty and the full agenda packed with industry-led sessions, take a look at the event brochure here.
With the market sky-rocketing and pipelines developing, this is your chance to be at the cutting edge.
To view your registration options, click here.